Chronic migraine is a neurological condition defined by having headaches on 15 or more days per month for at least three months, with at least 8 of those days meeting the criteria for migraine. That distinction matters: not every headache day needs to feel like a full migraine attack, but the majority should have migraine features like throbbing pain, nausea, or sensitivity to light and sound. About 2% to 3% of people with episodic migraine progress to chronic migraine each year.
How Chronic Migraine Differs From Episodic Migraine
The line between episodic and chronic migraine is drawn at 15 headache days per month. Below that threshold, you have episodic migraine. Cross it consistently for three months, and the diagnosis shifts to chronic. But the differences go well beyond frequency.
People with chronic migraine have attacks that last significantly longer. Untreated episodes average about 65 hours, compared to roughly 39 hours for episodic migraine. Even with treatment, chronic migraine attacks last nearly twice as long (about 24 hours versus 13 hours). Pain intensity tends to be more severe, and the days between attacks aren’t always pain-free. Many people with chronic migraine live with a low-grade background headache that occasionally escalates into a full migraine.
A skin sensitivity called cutaneous allodynia, where normal touch feels painful, affects about 68% of people with chronic migraine compared to 63% of those with episodic migraine. This seems like a small gap, but allodynia is more than a symptom. It’s a sign that the nervous system has become hypersensitive, and longitudinal research has identified it as an independent risk factor for migraine becoming chronic in the first place.
What Happens in the Brain
Chronic migraine isn’t simply more frequent attacks. It involves measurable changes in how the brain processes pain. The central concept is called central sensitization: pain-signaling neurons in the brain and spinal cord become increasingly responsive to normal input, effectively turning up the volume on pain. Over time, stimuli that wouldn’t normally register as painful start triggering a pain response.
A signaling molecule called CGRP plays a key role. CGRP is abundant in the nerve cells that connect the face and head to the brain. During a migraine, CGRP is released in large quantities, dilating blood vessels and amplifying pain signals. In chronic migraine, this system appears to stay persistently activated. CGRP interacts with surrounding nerve cells and support cells to keep sensitizing the pain pathway, creating a cycle where each attack makes the next one more likely.
Cortical spreading depression, a slow wave of electrical activity across the brain’s surface, also contributes. This wave sensitizes both peripheral and central pain neurons. Animal studies have shown that blocking CGRP with antibodies can prevent this sensitization from taking hold, which is the basis for an entire class of preventive treatments.
Risk Factors and What Drives Chronification
Several factors increase the likelihood of episodic migraine becoming chronic. Depression, anxiety, obesity, sleep disorders, and stressful life events all raise the risk. But one of the most common and preventable drivers is medication overuse headache.
Taking acute pain medications too frequently can paradoxically make headaches worse and more frequent. The thresholds are specific: using triptans, opioids, or combination painkillers on 10 or more days per month for three months can trigger medication overuse headache. For over-the-counter options like ibuprofen or acetaminophen, the threshold is 15 days per month. This doesn’t mean these medications are dangerous in normal use. It means that when headaches are frequent enough to require near-daily treatment, the treatment itself can become part of the problem.
Common Comorbidities
Chronic migraine rarely travels alone. Depression is roughly 2.8 times more common in people with migraine than in the general population, and among those with disabling chronic headache, major depressive disorder is dramatically overrepresented. Anxiety and panic disorder also co-occur at high rates, with panic disorder nearly doubling the risk of developing severe headaches.
Sleep disorders are another frequent companion. Restless legs syndrome affects 11% to 34% of migraine patients depending on the study, compared to less than 5% of people with tension-type headache. Cardiovascular conditions including stroke, coronary heart disease, and hypertension also appear on the list of comorbidities, along with asthma and epilepsy. These overlapping conditions can complicate treatment, but they also offer clues about the shared biological pathways involved.
Measuring the Impact
Doctors often use the Migraine Disability Assessment (MIDAS) to gauge how much migraine disrupts daily life. The scale asks about missed days of work, school, and household activities over the past three months. A score of 0 to 5 indicates little or no disability. Scores of 6 to 10 represent mild disability, 11 to 20 moderate disability, and anything above 21 means severe disability. Most people with chronic migraine score well into the severe range, reflecting the reality of losing multiple days per month to pain, nausea, and the cognitive fog that often accompanies attacks.
Preventive Treatment Options
Because chronic migraine involves ongoing changes in brain sensitivity, prevention is the cornerstone of treatment. The goal isn’t to eliminate every headache but to reduce monthly headache days enough to improve quality of life and, ideally, to reverse some of the nervous system changes driving chronification.
CGRP-Targeting Medications
The newest class of preventives works by blocking CGRP, the signaling molecule that drives migraine pain and sensitization. Four injectable antibodies are available, each given monthly or quarterly depending on the specific medication. In clinical trials involving people with chronic migraine, these treatments reduced monthly headache days by about 6 per month compared to roughly 4 days with placebo. For people also dealing with medication overuse headache, one of these antibodies reduced migraine days by about 5 per month.
These medications have a notable advantage: because they’re broken down into basic amino acids rather than processed through the liver, they carry very few drug interactions. That makes them a practical first choice for people already taking other medications.
Botox Injections
Botox is specifically approved for chronic migraine and works by blocking the release of CGRP and other pain-signaling chemicals from nerve fibers. The standard protocol involves 155 units divided across 31 injection sites around the head and neck, repeated every 12 weeks. It inhibits both peripheral and central sensitization, essentially interrupting the cycle that keeps the pain pathway overactive. Side effects tend to be mild, and the treatment has a strong safety record even when combined with oral preventive medications.
Oral Preventives
Several types of daily oral medications can reduce migraine frequency. These include certain blood pressure medications, antidepressants, and anti-seizure drugs, all of which were originally developed for other conditions but found to help with migraine. Some of these carry more side effects and drug interactions than CGRP blockers or Botox, which is why newer options are often preferred when access isn’t a barrier. Candesartan, a blood pressure medication, and melatonin stand out as having particularly low interaction profiles among oral options.
The Path From Chronic Back to Episodic
Chronic migraine is not necessarily permanent. With effective prevention, many people drop below the 15-day threshold and revert to episodic migraine. Addressing modifiable risk factors makes a significant difference: withdrawing from overused acute medications, treating depression or anxiety, improving sleep quality, and managing weight can all contribute to reducing headache frequency. The nervous system changes underlying chronic migraine appear to be at least partially reversible, particularly when treatment starts before the condition has been entrenched for years.